DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ridaforolimus
Ridaforolimus
WO 2018/223101 Al 06 December 2018 (06.12.2018) W !P O PCT
Physiologically Based Pharmacokinetic Modeling in Regulatory Decision‐Making at the European Medicines Agency
Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
Related Kinases (VRK) Bound to Small-Molecule Inhibitors Identifies Different P-Loop Conformations
Sarcoma Metabolomics: Current Horizons and Future Perspectives
Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
Withdrawal Assessment Report for Jenzyl, INN: RIDAFOROLIMUS
Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
WHO Drug Information Vol
Precision Medicine in Diffuse Large B-Cell Lymphoma: Hitting the Target Joost S
WO 2017/197056 Al 16 November 2017 (16.11.2017) W !P O PCT
Documents Numérisés Par Onetouch
Abteilung Fachberatung Medizin Recherche Und Synopse Der
Figure S1. Effect of 4NQO, A-1155463 Or Their Combination on General Transcription, Translation, and Specific Apoptotic Proteins
Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard of Care Therapy for Appendicular Osteosarcoma: a Prospective, Randomized Trial of 324 Dogs
Everolimus-Associated Stomatitis in a Patient Who Had Renal Transplant Yisi D Ji,1 Ali Aboalela,2 Alessandro Villa3
WO 2020/039060 A1 27 February 2020 (27.02.2020)
Applications for New Human Medicines Under Evaluation by the Committee for Medicinal Products for Human Use August 2012
Top View
Mtor Inhibition/Targeting in Solid Tumors
NDO Home | Contact | Register for NDO Access
Mtor Signaling in Cancer and Mtor Inhibitors in Solid Tumor Targeting Therapy
Strategies for the Management of Adverse Events Associated with Mtor Inhibitors
Supplemental Material 1
Mtor Signaling in Metabolism and Cancer
Università Degli Studi Di Catania
Supplementary Fig. S1
Rapalogs in Viral Cancers
Drug Eruptions Associated with Tumor Therapy: Great Imitators
Pharmaceutical Clinical Trials in New York in State Taxes and More Than $646 Million in Federal • Clinical Trials Are Responsible for 45 to 75 Percent of Taxation
ATC-Index Mit DDD-Angaben Für Den Deutschen Arzneimittelmarkt Berlin 2013, 12
A Phase 2, Multicenter, Open-Label Study of BGJ398 in Patients with Recurrent Resectable Or Unresectable Glioblastoma
ATC-Index Mit DDD-Angaben Für Deutschland Im Jahre 2019
Identification of Precision Treatment Strategies for Relapsed/ Refractory Multiple Myeloma by Functional Drug Sensitivity Testing
Strategies for the Management of Adverse Events Associated with Mtor Inhibitors
A Phase 1 Study of Oral Ridaforolimus in Pediatric Patients with Advanced Solid Tumors
Phase I Study for Ridaforolimus, an Oral Mtor Inhibitor, in Japanese Patients with Advanced Solid Tumors